Kohlberg Kravis Roberts & Co. L.P. Bridge Bio Pharma, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $1.54 Billion
- Q4 2024
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 25,260,971 shares of BBIO stock, worth $931 Million. This represents 44.98% of its overall portfolio holdings.
Number of Shares
25,260,971
Previous 25,260,971
-0.0%
Holding current value
$931 Million
Previous $643 Million
7.78%
% of portfolio
44.98%
Previous 35.94%
Shares
4 transactions
Others Institutions Holding BBIO
# of Institutions
321Shares Held
176MCall Options Held
13MPut Options Held
2.48M-
Viking Global Investors LP25.1MShares$926 Million2.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.1MShares$556 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$459 Million0.01% of portfolio
-
State Street Corp Boston, MA6.18MShares$228 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$224 Million61.0% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $5.46B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...